EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Extracellular Vesicle from Chlorella vulgaris Alleviates Hepatic Fibrosis in a Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease Through Modulation of Inflammatory Signaling

Hinata Harada, Yusuke Ohsaki, Afifah Zahra Agista, Hsin-Jung Ho iD, Takuo Hirose iD, Kotaro Yamada, Mutsumi Furukawa, Tomonori Nochi iD, Wan-Chun Chiu iD, Ya-Ling Chen, Chiu-Li Yeh iD, Suh-Ching Yang iD und 2 weitere

International Journal of Molecular Sciences · 22.04.2026 · 27 (9) · 3735

DOI: 10.3390/ijms27093735 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.04.2026. Verfasst von Hinata Harada und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Nutrition, Graduate School of Agricultural Science, Tohoku University, Sendai 980-8572, Japan. Hauptthemen laut MEDLINE: Chlorella vulgaris, Liver Cirrhosis, Extracellular Vesicles, Inflammation. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rohto Pharmaceutical (Japan), Tohoku University, ROHTO Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a major chronic liver disorder that progresses through inflammation and fibrosis to cirrhosis, yet no effective pharmacological therapy is available. Extracellular vesicles (EVs), which are key mediators of intercellular communication, have recently been reported to exert preventative and therapeutic effects in disease models. This study evaluated the oral efficacy of EVs derived from the microalga Chlorella vulgaris (CEVs) in an MASLD mouse model. Male C57BL/6J mice were assigned to a control group (normal diet), an MASLD group (choline- and methionine-deficient high-fat diet; CDHF), or CEV group (CDHF + CEVs). Twelve-week CEV administration did not alter the CDHF-induced reduction in circulating lipid levels or produce an increase in hepatic lipid content. However, CEV treatment significantly suppressed CDHF-induced fibrosis with collagen accumulation and reduced the mRNA expression of fibrosis-related genes, including Col1a1, Acta2, Mmp2, and Timp1. CEVs also significantly downregulated the expression of macrophage-derived inflammatory mediators—Ccl2, Ccr2, Il6 and Il1b—and reduced lobular inflammatory foci. These findings suggest that CEVs attenuate hepatic fibrosis by modulating early inflammation associated with steatosis and inhibiting hepatic stellate cell activation. This study supports the potential of CEVs as a novel oral intervention for slowing MASLD progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chlorella vulgarisLiver CirrhosisExtracellular VesiclesInflammationFatty LiverAnimalsMiceMaleMice, Inbred C57BLDisease Models, AnimalSignal TransductionLiverDiet, High-Fat

Stichwörter der Autor:innen

Chlorella vulgarisKupffer cellMASLDexosomeextracellular vesicleshepatic fibrosishepatic steatosisinflammationliver diseasemacrophagemicroalgae

Autor:innen und Institutionen

  • Laboratory of Nutrition, Graduate School of Agricultural Science, Tohoku University, Sendai 980-8572, Japan.
  • International Education and Research Center for Food Agricultural Immunology, Graduate School of Agricultural Science, Tohoku University, Sendai 980-8572, Japan.
  • Institute for Excellence in Higher Education, Tohoku University, Sendai 980-8576, Japan.
  • Division of Physiology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Japan.
  • Division of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Japan.
  • Division of Integrative Renal Replacement Therapy, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai 983-8536, Japan.

ORCID-Profile: Hsin-Jung Ho, Takuo Hirose, Tomonori Nochi, Wan-Chun Chiu, Chiu-Li Yeh, Suh-Ching Yang, Hitoshi Shirakawa

Förderung

  • Rohto Pharmaceutical (Japan)
  • Tohoku University
  • ROHTO Pharmaceutical Co., Ltd.

Zitieren

APA

Harada, H., Ohsaki, Y., Agista, A. Z., Ho, H. J., Hirose, T., Yamada, K., Furukawa, M., Nochi, T., Chiu, W. C., Chen, Y. L., Yeh, C. L., Yang, S. C., Mori, T., & Shirakawa, H. (2026). Extracellular Vesicle from Chlorella vulgaris Alleviates Hepatic Fibrosis in a Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease Through Modulation of Inflammatory Signaling. International Journal of Molecular Sciences, 27(9), 3735. https://doi.org/10.3390/ijms27093735

Vancouver

Harada H, Ohsaki Y, Agista AZ, Ho HJ, Hirose T, Yamada K, et al. Extracellular Vesicle from Chlorella vulgaris Alleviates Hepatic Fibrosis in a Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease Through Modulation of Inflammatory Signaling. International Journal of Molecular Sciences. 2026;27(9):3735. doi:10.3390/ijms27093735

BibTeX
@article{Harada2026,
  author = {Harada, Hinata and Ohsaki, Yusuke and Agista, Afifah Zahra and Ho, Hsin-Jung and Hirose, Takuo and Yamada, Kotaro and Furukawa, Mutsumi and Nochi, Tomonori and Chiu, Wan-Chun and Chen, Ya-Ling and Yeh, Chiu-Li and Yang, Suh-Ching and Mori, Takefumi and Shirakawa, Hitoshi},
  title = {Extracellular Vesicle from Chlorella vulgaris Alleviates Hepatic Fibrosis in a Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease Through Modulation of Inflammatory Signaling},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {9},
  pages = {3735},
  doi = {10.3390/ijms27093735}
}
Kostenlos starten →